Richard Steinhart - 31 Mar 2025 Form 4 Insider Report for Actinium Pharmaceuticals, Inc. (ATNM)

Role
Director
Signature
/s/ Richard Steinhart
Issuer symbol
ATNM
Transactions as of
31 Mar 2025
Net transactions value
$0
Form type
4
Filing time
02 Apr 2025, 18:22:33 UTC
Previous filing
17 Mar 2025
Next filing
16 May 2025
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -2,500 -100% $0.000000 0 31 Mar 2025 Common Stock 2,500 $59.70 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -2,500 -100% $0.000000 0 31 Mar 2025 Common Stock 2,500 $41.70 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -2,500 -100% $0.000000 0 31 Mar 2025 Common Stock 2,500 $23.49 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -8,333 -100% $0.000000 0 31 Mar 2025 Common Stock $8,333 $6.96 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -8,333 -100% $0.000000 0 31 Mar 2025 Common Stock 8,333 $9.55 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -18,351 -100% $0.000000 0 31 Mar 2025 Common Stock 18,351 $6.07 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -72,156 -100% $0.000000 0 31 Mar 2025 Common Stock 72,156 $4.96 Direct F1
transaction ATNM Stock Option (Right to Buy) Disposed to Issuer $0 -70,311 -100% $0.000000 0 31 Mar 2025 Common Stock 70,311 $5.00 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Pursuant to that certain Option Cancellation and Release Agreement, dated as of March 31, 2025, by and between the Issuer and the Reporting Person, the Reporting Person agreed to cancel the reported stock options to purchase shares of common stock, par value $0.001 per share, of the Issuer effective March 31, 2025, in exchange for nominal consideration.